HUMAN PAPILLOMAVIRUS (HPV) AND CYTOMEGALOVIRUS (CMV) THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Cytomegalovirus (CMV) infections spread through body fluids such as saliva, semen, breast milk, and urine. Signs and symptoms of the infections include, fatigue, fever, diarrhea, pneumonia, and hepatitis, shortness of breath, gastrointestinal ulceration, and bleeding.

Although no treatment for the infection caused by human papillomavirus (HPV) is available, symptoms can be treated. Most sexually active men and women suffer from HPV infections. The infections spread through oral, vaginal or anal sex. HPV can also be transmitted during birth to infant and can lead to genital or respiratory infections.

Market Dynamics

Increasing collaboration activities of major players is expected to propel growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market. For instance, in November 2018, GeoVax Labs Inc. announced collaboration with Virometix. The collaboration focuses on development of therapeutic vaccines for HPV infections. This collaboration will include preclinical animal testing of GeoVax’s MVA-Vectored HPV vaccines candidates in combination with Virometix synthetic HPV vaccines candidates.

Moreover, increasing regulatory approvals for novel therapies is expected to boost the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth. For instance, in November 2017, Merck received the U.S. Food and Drug Administration approval for its Prevymis (letermovir) tablets and intravenous (IV) injection for prophylaxis of CMV infections and CMV seropositive recipients.

Key features of the study

• This report provides in-depth analysis of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market size (US$ Mn), and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, , Allergan, Bausch Health, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding AG, Biotest AG, and Fresenius Kabi
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for anesthesia device market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• By Drug Type
• HPV Therapeutics
• Immunomodulatory Agents
• Interleukins
• Cytokines
• Chemokine
• Others
• Keratolytic Agents
• TCA
• Bichloracetic Acid
• Anti-neoplastic Agents
• Sinecatechins
• CMV Therapeutics
• Ganciclovir/ Valaganciclovir
• Foscarnet
• Cidifovir
• By Application
• HPV Therapeutics Application
• Genital warts
• Cervical cancer
• Epidermodysplasia Verrucifdormis
• Others
• CMV Therapeutics Application
• CMV Retinitis
• Pneumonia
• Gastrointestinal ulcers
• Encephalitis
• Others
• By Distribution Chanel
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
• Human Papillomavirus (HPV) And Cytomegalovirus (CMV) Therapeutics Market Companies
  • Allergan
  • Bausch Health
  • GlaxoSmithKline
  • Lee’s Pharmaceutical Holdings
  • Merck Sharp & Dohme
  • Fougera Pharmaceuticals
  • Clinigen Group plc
  • Perrigo Company plc
  • Roche Holding AG
  • Biotest AG
  • Fresenius Kabi